WeVote
Log In

Bill

Bill

SB 494

AN ACT CONCERNING PRESCRIPTION DRUG SHORTAGES, PRESCRIPTION DRUG REBATES AND PROHIBITED MANUFACTURER PRACTICES CONCERNING CERTAIN PRESCRIPTION DRUGS.

2026 Regular Session Introduced by Martin Looney

Connecticut bill authorizes implementation of bipartisan task force recommendations on prescription drug policy to improve affordability and access.

FILE NO. 483
#drugs #economicandcommunitydevelopment #departmentof #emergencies #pharmaceuticalmanufacturingcompanies #rebates #reports #socialservices #statemedicalassistanceprogram #studies #taskforces #consumerprotectiondepartment #fines(penalties) #violations
0
WeVote Research Nonpartisan
Bill Summary · SB 494

Legislative bill overview

SB 494 directs Connecticut to implement recommendations from a bipartisan prescription drug task force. The bill appears to authorize or mandate action on drug pricing, access, or affordability measures that the task force previously developed. Specific policy details would depend on what recommendations the referenced task force actually made.

Why is this important

Prescription drug costs remain a significant burden for Connecticut residents and the state budget. Task force recommendations typically address drug pricing transparency, generic drug access, or pharmaceutical purchasing strategies that could affect healthcare affordability for individuals and state programs like Medicaid.

Potential points of contention

  • Implementation costs and funding: Whether the state budget will adequately cover expenses associated with task force recommendations
  • Pharmaceutical industry impact: Recommendations on pricing or purchasing may face resistance from drug manufacturers or wholesale distributors
  • Scope and enforceability: Unclear whether recommendations are suggestions or binding mandates, and which state agencies bear responsibility for implementation

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.